Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Conditions

Myasthenia Gravis 3

Interventions

Cyclophosphamide 3160Cisplatin 3157Carboplatin 2934Paclitaxel 2672Radiotherapy 2644Gemcitabine 2547pembrolizumab 2328Docetaxel 2157Bevacizumab 2128Fluorouracil 1822Capecitabine 1782Oxaliplatin 1713Dexamethasone 1589Nivolumab 1517Doxorubicin 1477Rituximab 1454Etoposide 1341Magnetic Resonance Spectroscopy 1264Irinotecan 1235Leucovorin 1215Cytarabine 1123Drug Therapy 1061Pemetrexed 1060fludarabine 1048Vincristine 956Specimen Handling 935Prednisone 925Cetuximab 921Lenalidomide 916Trastuzumab 901

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × HBM9161 × Clear all
NCT05332210 2026-04-28

Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis

Harbour BioMed (Guangzhou) Co. Ltd.

Phase 3 Completed
111 enrolled

Myasthenia Gravis

NCT04346888 2023-03-08

A Study to Evaluate the Efficacy, Safety and PD and PK of HBM9161 in MG Patients

Harbour BioMed (Guangzhou) Co. Ltd.

Phase 2 Completed
30 enrolled

Myasthenia Gravis

NCT05039190 2023-03-08

MG

Harbour BioMed (Guangzhou) Co. Ltd.

Phase 3 Completed
132 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡